Listed

Cogent Biosciences, Inc.

COGTNasdaqCIK 1622229HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$102.6m, Q2 FY2026
Net income−$96.4m, Q2 FY2026
Cogent Biosciences, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m50.1Research and development, Q3 FY2023, three months to 2023-09-30$50.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0000950170-24-124712.Report this figure48.7Research and development, Q4 FY2023, three months to 2023-12-31$48.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-17, accession 0001193125-26-053334. Derived: 12-month figure less the 9-month figure.Report this figure52.7Research and development, Q1 FY2024, three months to 2024-03-31$52.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-06, accession 0000950170-25-064005.Report this figure54.3Research and development, Q2 FY2024, three months to 2024-06-30$54.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-05, accession 0000950170-25-102440.Report this figure63.6Research and development, Q3 FY2024, three months to 2024-09-30$63.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure62.0Research and development, Q4 FY2024, three months to 2024-12-31$62.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-17, accession 0001193125-26-053334. Derived: 12-month figure less the 9-month figure.Report this figure63.0Research and development, Q1 FY2025, three months to 2025-03-31$63.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure62.2Research and development, Q2 FY2025, three months to 2025-06-30$62.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure69.0Research and development, Q3 FY2025, three months to 2025-09-30$69.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure75.6Research and development, Q4 FY2025, three months to 2025-12-31$75.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-17, accession 0001193125-26-053334. Derived: 12-month figure less the 9-month figure.Report this figure75.4Research and development, Q1 FY2026, three months to 2026-03-31$75.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure70.8Research and development, Q2 FY2026, three months to 2026-06-30$70.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure
Operating income$m(59.6)Operating income, Q3 FY2023, three months to 2023-09-30−$59.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0000950170-24-124712.Report this figure(58.2)Operating income, Q4 FY2023, three months to 2023-12-31−$58.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0001193125-26-053334. Derived: 12-month figure less the 9-month figure.Report this figure(62.4)Operating income, Q1 FY2024, three months to 2024-03-31−$62.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-06, accession 0000950170-25-064005.Report this figure(64.4)Operating income, Q2 FY2024, three months to 2024-06-30−$64.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-05, accession 0000950170-25-102440.Report this figure(75.4)Operating income, Q3 FY2024, three months to 2024-09-30−$75.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure(73.7)Operating income, Q4 FY2024, three months to 2024-12-31−$73.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0001193125-26-053334. Derived: 12-month figure less the 9-month figure.Report this figure(74.9)Operating income, Q1 FY2025, three months to 2025-03-31−$74.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure(75.6)Operating income, Q2 FY2025, three months to 2025-06-30−$75.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure(83.4)Operating income, Q3 FY2025, three months to 2025-09-30−$83.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure(99.5)Operating income, Q4 FY2025, three months to 2025-12-31−$99.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0001193125-26-053334. Derived: 12-month figure less the 9-month figure.Report this figure(104)Operating income, Q1 FY2026, three months to 2026-03-31−$103.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure(103)Operating income, Q2 FY2026, three months to 2026-06-30−$102.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reported0.3Interest expense, Q2 FY2025, three months to 2025-06-30$314.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure1.5Interest expense, Q3 FY2025, three months to 2025-09-30$1.5m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure1.3Interest expense, Q4 FY2025, three months to 2025-12-31$1.3m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-02-17, accession 0001193125-26-053334. Derived: 12-month figure less the 9-month figure.Report this figure1.2Interest expense, Q1 FY2026, three months to 2026-03-31$1.2m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure1.2Interest expense, Q2 FY2026, three months to 2026-06-30$1.2m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(55.4)Net income, Q3 FY2023, three months to 2023-09-30−$55.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0000950170-24-124712.Report this figure(54.4)Net income, Q4 FY2023, three months to 2023-12-31−$54.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-17, accession 0001193125-26-053334. Derived: 12-month figure less the 9-month figure.Report this figure(58.3)Net income, Q1 FY2024, three months to 2024-03-31−$58.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure(59.0)Net income, Q2 FY2024, three months to 2024-06-30−$59.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure(70.6)Net income, Q3 FY2024, three months to 2024-09-30−$70.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure(67.9)Net income, Q4 FY2024, three months to 2024-12-31−$67.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-17, accession 0001193125-26-053334. Derived: 12-month figure less the 9-month figure.Report this figure(72.0)Net income, Q1 FY2025, three months to 2025-03-31−$72.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure(73.5)Net income, Q2 FY2025, three months to 2025-06-30−$73.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure(80.9)Net income, Q3 FY2025, three months to 2025-09-30−$80.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure(102)Net income, Q4 FY2025, three months to 2025-12-31−$102.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-17, accession 0001193125-26-053334. Derived: 12-month figure less the 9-month figure.Report this figure(97.4)Net income, Q1 FY2026, three months to 2026-03-31−$97.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure(96.4)Net income, Q2 FY2026, three months to 2026-06-30−$96.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure
Diluted EPS$ per share(0.64)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.64 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0000950170-24-124712.Report this figurenot reported(0.49)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-06, accession 0000950170-25-064005.Report this figure(0.43)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-05, accession 0000950170-25-102440.Report this figure(0.52)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figurenot reported(0.52)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure(0.53)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure(0.50)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.50 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figurenot reported(0.53)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure(0.52)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure
Basic EPS$ per share(0.64)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.64 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0000950170-24-124712.Report this figurenot reported(0.49)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.49 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-06, accession 0000950170-25-064005.Report this figure(0.43)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.43 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-05, accession 0000950170-25-102440.Report this figure(0.52)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.52 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figurenot reported(0.52)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.52 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure(0.53)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.53 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure(0.50)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.50 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figurenot reported(0.53)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.53 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure(0.52)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.52 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure

Balance sheet

Cash and equivalents$181.2m, Q2 FY2026
Long-term debt$223.5m, Q2 FY2026
Shareholders' equity$532.4m, Q2 FY2026
Cogent Biosciences, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m86.8Cash and equivalents, Q3 FY2023, at 2023-09-30$86.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-07, accession 0000950170-23-059769.Report this figure53.2Cash and equivalents, FY2023, at 2023-12-31$53.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-25, accession 0000950170-25-026115.Report this figure216Cash and equivalents, Q1 FY2024, at 2024-03-31$215.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-07, accession 0000950170-24-053977.Report this figure88.2Cash and equivalents, Q2 FY2024, at 2024-06-30$88.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-06, accession 0000950170-24-091229.Report this figure97.0Cash and equivalents, Q3 FY2024, at 2024-09-30$97.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0000950170-24-124712.Report this figure98.2Cash and equivalents, FY2024, at 2024-12-31$98.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-17, accession 0001193125-26-053334.Report this figure126Cash and equivalents, Q1 FY2025, at 2025-03-31$126.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-06, accession 0000950170-25-064005.Report this figure128Cash and equivalents, Q2 FY2025, at 2025-06-30$127.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-05, accession 0000950170-25-102440.Report this figure125Cash and equivalents, Q3 FY2025, at 2025-09-30$125.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure312Cash and equivalents, FY2025, at 2025-12-31$312.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure241Cash and equivalents, Q1 FY2026, at 2026-03-31$241.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure181Cash and equivalents, Q2 FY2026, at 2026-06-30$181.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure
Current assets$m286Current assets, Q3 FY2023, at 2023-09-30$286.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-07, accession 0000950170-23-059769.Report this figure271Current assets, FY2023, at 2023-12-31$270.8m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-25, accession 0000950170-25-026115.Report this figure442Current assets, Q1 FY2024, at 2024-03-31$441.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-07, accession 0000950170-24-053977.Report this figure370Current assets, Q2 FY2024, at 2024-06-30$370.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-06, accession 0000950170-24-091229.Report this figure342Current assets, Q3 FY2024, at 2024-09-30$341.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0000950170-24-124712.Report this figure296Current assets, FY2024, at 2024-12-31$296.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-17, accession 0001193125-26-053334.Report this figure253Current assets, Q1 FY2025, at 2025-03-31$252.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-06, accession 0000950170-25-064005.Report this figure245Current assets, Q2 FY2025, at 2025-06-30$245.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-05, accession 0000950170-25-102440.Report this figure397Current assets, Q3 FY2025, at 2025-09-30$397.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure910Current assets, FY2025, at 2025-12-31$910.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure878Current assets, Q1 FY2026, at 2026-03-31$877.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure805Current assets, Q2 FY2026, at 2026-06-30$804.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure
Total assets$m355Total assets, Q3 FY2023, at 2023-09-30$355.4m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-07, accession 0000950170-23-059769.Report this figure313Total assets, FY2023, at 2023-12-31$313.4m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-25, accession 0000950170-25-026115.Report this figure476Total assets, Q1 FY2024, at 2024-03-31$476.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-07, accession 0000950170-24-053977.Report this figure430Total assets, Q2 FY2024, at 2024-06-30$429.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-06, accession 0000950170-24-091229.Report this figure384Total assets, Q3 FY2024, at 2024-09-30$384.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0000950170-24-124712.Report this figure328Total assets, FY2024, at 2024-12-31$327.9m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-17, accession 0001193125-26-053334.Report this figure284Total assets, Q1 FY2025, at 2025-03-31$283.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-06, accession 0000950170-25-064005.Report this figure275Total assets, Q2 FY2025, at 2025-06-30$274.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-05, accession 0000950170-25-102440.Report this figure426Total assets, Q3 FY2025, at 2025-09-30$425.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure938Total assets, FY2025, at 2025-12-31$937.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure903Total assets, Q1 FY2026, at 2026-03-31$903.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure835Total assets, Q2 FY2026, at 2026-06-30$834.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure
Current liabilities$m34.7Current liabilities, Q3 FY2023, at 2023-09-30$34.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-07, accession 0000950170-23-059769.Report this figure38.2Current liabilities, FY2023, at 2023-12-31$38.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-25, accession 0000950170-25-026115.Report this figure36.7Current liabilities, Q1 FY2024, at 2024-03-31$36.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-07, accession 0000950170-24-053977.Report this figure40.0Current liabilities, Q2 FY2024, at 2024-06-30$40.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-06, accession 0000950170-24-091229.Report this figure53.0Current liabilities, Q3 FY2024, at 2024-09-30$53.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0000950170-24-124712.Report this figure55.7Current liabilities, FY2024, at 2024-12-31$55.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-17, accession 0001193125-26-053334.Report this figure49.3Current liabilities, Q1 FY2025, at 2025-03-31$49.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-06, accession 0000950170-25-064005.Report this figure58.4Current liabilities, Q2 FY2025, at 2025-06-30$58.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-05, accession 0000950170-25-102440.Report this figure62.2Current liabilities, Q3 FY2025, at 2025-09-30$62.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure64.0Current liabilities, FY2025, at 2025-12-31$64.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure58.0Current liabilities, Q1 FY2026, at 2026-03-31$58.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure59.3Current liabilities, Q2 FY2026, at 2026-06-30$59.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure
Total liabilities$m52.5Total liabilities, Q3 FY2023, at 2023-09-30$52.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-07, accession 0000950170-23-059769.Report this figure55.6Total liabilities, FY2023, at 2023-12-31$55.6m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-25, accession 0000950170-25-026115.Report this figure53.8Total liabilities, Q1 FY2024, at 2024-03-31$53.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-07, accession 0000950170-24-053977.Report this figure56.7Total liabilities, Q2 FY2024, at 2024-06-30$56.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-06, accession 0000950170-24-091229.Report this figure69.4Total liabilities, Q3 FY2024, at 2024-09-30$69.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0000950170-24-124712.Report this figure71.6Total liabilities, FY2024, at 2024-12-31$71.6m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-17, accession 0001193125-26-053334.Report this figure64.8Total liabilities, Q1 FY2025, at 2025-03-31$64.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-06, accession 0000950170-25-064005.Report this figure120Total liabilities, Q2 FY2025, at 2025-06-30$119.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-05, accession 0000950170-25-102440.Report this figure123Total liabilities, Q3 FY2025, at 2025-09-30$123.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure301Total liabilities, FY2025, at 2025-12-31$301.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure295Total liabilities, Q1 FY2026, at 2026-03-31$295.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure302Total liabilities, Q2 FY2026, at 2026-06-30$302.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reported0.0Long-term debt, FY2024, at 2024-12-31$0. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figurenot reported43.9Long-term debt, Q2 FY2025, at 2025-06-30$43.9m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-08-05, accession 0000950170-25-102440.Report this figure44.3Long-term debt, Q3 FY2025, at 2025-09-30$44.3m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure223Long-term debt, FY2025, at 2025-12-31$222.9m. XBRL concept us-gaap:LongTermDebt. 10-K filed 2026-02-17, accession 0001193125-26-053334.Report this figure223Long-term debt, Q1 FY2026, at 2026-03-31$223.2m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure223Long-term debt, Q2 FY2026, at 2026-06-30$223.5m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure
Shareholders' equity$m303Shareholders' equity, Q3 FY2023, at 2023-09-30$302.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0000950170-24-124712.Report this figure258Shareholders' equity, FY2023, at 2023-12-31$257.8m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-17, accession 0001193125-26-053334.Report this figure422Shareholders' equity, Q1 FY2024, at 2024-03-31$422.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure373Shareholders' equity, Q2 FY2024, at 2024-06-30$373.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure315Shareholders' equity, Q3 FY2024, at 2024-09-30$314.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure256Shareholders' equity, FY2024, at 2024-12-31$256.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure219Shareholders' equity, Q1 FY2025, at 2025-03-31$219.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure155Shareholders' equity, Q2 FY2025, at 2025-06-30$155.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure302Shareholders' equity, Q3 FY2025, at 2025-09-30$302.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure636Shareholders' equity, FY2025, at 2025-12-31$636.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure608Shareholders' equity, Q1 FY2026, at 2026-03-31$607.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure532Shareholders' equity, Q2 FY2026, at 2026-06-30$532.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure

Cash flow

Operating cash flow−$77.3m, Q2 FY2026
Capital expenditure$370.0k, Q2 FY2026
Cogent Biosciences, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(38.0)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$38.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0000950170-24-124712. Derived: 9-month figure less the 6-month figure.Report this figure(44.1)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$44.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0001193125-26-053334. Derived: 12-month figure less the 9-month figure.Report this figure(52.5)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$52.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-06, accession 0000950170-25-064005.Report this figure(42.7)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$42.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-05, accession 0000950170-25-102440. Derived: 6-month figure less the 3-month figure.Report this figure(52.0)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$52.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-07, accession 0001193125-25-272334. Derived: 9-month figure less the 6-month figure.Report this figure(60.6)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$60.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0001193125-26-053334. Derived: 12-month figure less the 9-month figure.Report this figure(66.5)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$66.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure(54.5)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$54.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001193125-26-342393. Derived: 6-month figure less the 3-month figure.Report this figure(64.3)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$64.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-07, accession 0001193125-25-272334. Derived: 9-month figure less the 6-month figure.Report this figure(79.1)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$79.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0001193125-26-053334. Derived: 12-month figure less the 9-month figure.Report this figure(86.9)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$86.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure(77.3)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$77.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001193125-26-342393. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.1Capital expenditure, Q3 FY2023, three months to 2023-09-30$121.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-12, accession 0000950170-24-124712. Derived: 9-month figure less the 6-month figure.Report this figure0.3Capital expenditure, Q4 FY2023, three months to 2023-12-31$315.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0001193125-26-053334. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2024, three months to 2024-03-31$70.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-06, accession 0000950170-25-064005.Report this figure0.1Capital expenditure, Q2 FY2024, three months to 2024-06-30$148.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-05, accession 0000950170-25-102440. Derived: 6-month figure less the 3-month figure.Report this figure0.3Capital expenditure, Q3 FY2024, three months to 2024-09-30$280.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-07, accession 0001193125-25-272334. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2024, three months to 2024-12-31$75.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0001193125-26-053334. Derived: 12-month figure less the 9-month figure.Report this figure0.5Capital expenditure, Q1 FY2025, three months to 2025-03-31$547.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure0.1Capital expenditure, Q2 FY2025, three months to 2025-06-30$131.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001193125-26-342393. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2025, three months to 2025-09-30$65.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-07, accession 0001193125-25-272334. Derived: 9-month figure less the 6-month figure.Report this figure0.8Capital expenditure, Q4 FY2025, three months to 2025-12-31$811.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0001193125-26-053334. Derived: 12-month figure less the 9-month figure.Report this figure0.4Capital expenditure, Q1 FY2026, three months to 2026-03-31$449.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure0.4Capital expenditure, Q2 FY2026, three months to 2026-06-30$370.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001193125-26-342393. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)171.01m, Q2 FY2026
Cogent Biosciences, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares69.6Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3069,576,359 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-07, accession 0000950170-23-059769.Report this figure70.7Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3170,734,950 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-07, accession 0000950170-24-053977.Report this figure74.8Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3074,753,269 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-06, accession 0000950170-24-091229.Report this figure86.2Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3086,165,951 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0000950170-24-124712.Report this figure94.8Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3194,804,659 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-06, accession 0000950170-25-064005.Report this figure99.2Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3099,240,030 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-05, accession 0000950170-25-102440.Report this figure110Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30110,165,580 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure113Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31113,307,940 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure114Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30114,466,080 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure138Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30137,550,159 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-07, accession 0001193125-25-272334.Report this figure162Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31162,194,778 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-05, accession 0001193125-26-205170.Report this figure171Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30171,005,468 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure

Shares outstanding: 173.52mShares outstanding, period not labelled, at 2026-08-06173,524,982 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-342393.Report this figure at Aug 6, 2026, from the cover of the 10-Q filed Aug 10, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. Listed shows no prices and gives no investment advice.